Key result
Desmopressin acetate increased von Willebrand factor antigen levels but did not alter platelet aggregation, bleeding time, or postoperative blood loss compared with placebo in CABG patients.
Why the study?
Does desmopressin acetate alter platelet aggregation, von Willebrand factor antigen levels, and postoperative blood loss in patients undergoing uncomplicated coronary artery bypass surgery?
RCT (n=19)
Double-blind
parallel group
Does desmopressin acetate alter platelet aggregation, von Willebrand factor antigen levels, and postoperative blood loss in patients undergoing uncomplicated coronary artery bypass surgery?
Desmopressin acetate increases von Willebrand factor antigen levels but does not improve platelet aggregation or reduce blood loss in uncomplicated CABG patients.
No takes yet. Share an insight, caveat, or question.
Does not reduce blood loss in uncomplicated CABG; challenges routine use and extends negative RCT evidence against perioperative desmopressin.
Andersson et al. (1990) conducted an RCT in Uncomplicated coronary artery bypass operations with extracorporeal circulation (n=19). Desmopressin acetate (DDAVP) vs. Placebo was evaluated on Postoperative blood loss and bleeding time. Desmopressin acetate increased von Willebrand factor antigen levels but did not alter platelet aggregation, bleeding time, or postoperative blood loss compared with placebo in CABG patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: